Isabelle Imbert received the insignia of Knight of the French Légion d’Honneur from Dr Pierre Petitbon, President of the Orne Society of Members of the Legion of Honour, accompanied by his counterpart for Marseille, Guy Dabadie. This award follows her long-time work on SARS-CoV.
Our collaborative paper “Combining DEVS and semantic technologies for modeling the SARS-CoV-2 replication machinery” has received the Best Paper Award of the Annual Modeling and Simulation Conference 2021.
Feel free to read the article just here : https://fr.calameo.com/read/005154450e360a49aa8bd
We are pleased to welcome Marion and India, who joined the team as engineers to work on the Covid-19 project. Welcome girls !
La société des membres de la Légion d’Honneur de l’Orne soutient notre projet sur le COVID-19.
Un grand merci à eux !
If you want to learn more about Covid-19 and its genome, listen to Isabelle Imbert’s latest interview on the CNRS playlist #COVID19 La parole à la science (the word to science).
https://soundcloud.com/cnrs_officiel/genome-du-coronavirus?in=cnrs_officiel/sets/covid19-parole-a-la-science (French interview)
You can listen to Isabelle Imbert’s new interview about the Covid-19 outbreak on the France Culture website (French interview).
You can listen (or listen again) Isabelle Imbert’s interview about the Cryo-EM structure of the Covid-19 spike protein (French interview).
You can go to read Isabelle’s latest interview in the “vrai ou fake” Franceinfo section : Is a bat bite in the laboratory the cause of the epidemic? (French interview)
Strikingly, SARS-CoV and MERS-CoV-infected patients are insensitive to ribavirin, a FDA-approved broad-spectrum antiviral drug. Here, we report an unprecedented RNA correction machinery that was developed by the SARS-CoV. We show that the viral 3’-5’ exonuclease is able to excise either a misincorporated ribonucleotide or ribavirin 5’-monophosphate and to resume RNA synthesis. This proofreading pathway has allowed coronavirus RNA genome size expansion (~ 32 kb in size). This work paves the way for the design of future antiviral strategies using nucleoside analogues.